Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
33 enrolled 14 charts
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Phase 2 Terminated
1 enrolled 1 chart
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Phase NA Completed
23 enrolled 8 charts
VCR
Phase 2 Completed
24 enrolled 11 charts
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
32 enrolled 12 charts
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Phase 1 Completed
18 enrolled
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Phase 2 Completed
21 enrolled 10 charts
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 1/2 Completed
79 enrolled 19 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
Phase NA Terminated
3 enrolled 6 charts
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
Phase 1 Completed
12 enrolled
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Phase 2 Terminated
10 enrolled 7 charts
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 6 charts
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
Phase 2 Terminated
14 enrolled 9 charts
Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
15 enrolled
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Phase 1/2 Completed
107 enrolled
PS-341 in Treating Patients With Advanced Cancer
Phase 1 Completed
A Phase 2 Study of Velcadeâ„¢ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
Phase 2 Terminated
87 enrolled